Hutchison MediPharma | Press Releases

29-Nov-2018

HMP Enters into Multiple Collaborations to Evaluate Combinations of Surufatinib and Fruquintinib with PD-1 Checkpoint Inhibitors

26-Nov-2018

HMP Announces First Commercial Launch of Fruquintinib Capsules (Elunate®)

16-Nov-2018

HMP Announces Phase III FALUCA Trial Results for Fruquintinib in Third-Line, Advanced Non-Small Cell Lung Cancer in China

05-Sep-2018

HMP Announces the Approval of Fruquintinib Capsules for Previously Treated Colorectal Cancer in China

23-Jul-2018

HMP Initiates a Phase Ib/II Proof-of-Concept Trial of Sulfatinib in Pancreatic Neuroendocrine Tumors and Biliary Tract Cancer in the United States

04-Jun-2018

HMP Presents Further Fruquintinib FRESCO Trial Data at ASCO 2018 Annual Meeting

06-Mar-2018

HMP Initiates a Phase Ib/II Proof-of-Concept Trial of Epitinib in Glioblastoma in China

13-Feb-2018

HMP Completes Enrollment of 527 Patients in Pivotal Phase III FALUCA Trial with Fruquintinib in Lung Cancer

15-Dec-2017

HMP Initiates Fruquintinib U.S. Clinical Trials

31-Oct-2017

HMP Initiates FRUTIGA, a Phase III Trial of Fruquintinib in Second-Line Gastric Cancer